CX-2009 Abstract and CX-072 Abstract - Mark Stroh Ph.D. - CytomX Therapeutics @CytomXInc #PROCLAIM-CX-072 #proclaimcx072 #cx2009

CX-2009 Abstract and CX-072 Abstract - Mark Stroh Ph.D. - CytomX Therapeutics @CytomXInc #PROCLAIM-CX-072 #proclaimcx072 #cx2009

User Photo
Cancer-News

3 weeks
12 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Mark Stroh, Ph.D. - CytomX Therapeutics discusses CX-2009 Abstract - a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer and CX-072 Abstract - Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab.

ASCO2020

CX-2009

https://meetinglibrary.asco.org/record/188112/abstractPROCLAIM-

CX072

https://meetinglibrary.asco.org/record/186711/abstract

 

Up Next Autoplay